Who Owns Remodulin?

Martine Rothblatt founded United Therapeutics in 1996 after her daughter was diagnosed with pulmonary arterial hypertension, a rare and progressive disease of the lung arteries with no cure and limited treatments. The company licensed rights to develop treprostinil, a stable prostacyclin analog, and built its development program around making prostacyclin therapy practical outside of hospital-managed intravenous systems.

At the time, the standard prostacyclin therapy required continuous intravenous infusion of an unstable compound through a surgically placed central line, with a refrigerated cassette that had to be changed frequently. Treprostinil's chemical stability allowed room-temperature storage and, critically, subcutaneous delivery through a small pump similar to an insulin pump.

The FDA approved Remodulin for subcutaneous administration in 2002, and the drug reached the US market that year as United Therapeutics' first commercial product. Intravenous administration was approved in 2004, giving physicians both delivery routes for a molecule stable enough to not require the complex handling of earlier prostacyclins.

The commercial launch built United Therapeutics from a development-stage company into a profitable biotech. Remodulin revenue funded the development of inhaled treprostinil, approved as Tyvaso in 2009, and oral treprostinil, approved as Orenitram in 2013, completing a delivery-form franchise around the same molecule.

Competition arrived through generics. Treprostinil injection lost exclusivity, and generic versions entered the US market beginning around 2019, pressuring Remodulin's price and share. United Therapeutics responded through the Remunity pump program, pairing the branded drug with proprietary delivery devices, and through the 2025 launch of the next-generation RemunityPRO subcutaneous pump. Generic competition has contributed to a gradual revenue decline from the product's peak.

Remodulin generated $526.8 million in 2025, down 2 percent from $538.1 million in 2024. Fourth quarter 2025 worldwide revenue was $128 million, down 5 percent year over year, with the decline concentrated in the US market where generic infused treprostinil continues to take share. It nonetheless remains the most prescribed parenteral prostacyclin in the country.